Zobrazeno 1 - 6
of 6
pro vyhledávání: '"329"'
Autor:
Romain Guieze, Anne Calleja, Loic Ysebaert, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Fontanet Bijou, Anne Quinquenel, Annie Brion, Kamel Laribi
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Ibrutinib has revolutionized the management of RR CLL in the past 5 years, improving overall survival (OS) over standard chemo-immunotherapies (CIT) in the registration trials HELIOS and RESONATE. Recently, based on these two studies, a score has bee
Autor:
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Christopher R. Flowers, Jeffrey M. Switchenko
Publikováno v:
Blood. 134:3416-3416
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. Patients exhibit a 30%-40% relapse/refractory rate on standard first-line therapy and are known to have poor outcomes with relapsed/refractory disease, indicating a
Autor:
Evandro D. Bezerra, Brenda M. Sandmaier, Linde M. Morsink, Megan Othus, H. Joachim Deeg, H. Gary Schoch, Brent L. Wood, Min Fang, Frederick R. Appelbaum, Roland B. Walter
Publikováno v:
Blood. 134:321-321
Background:Myeloablative allogeneic hematopoietic cell transplantation (HCT) is a common post-remission treatment strategy for medically fit adults with acute myeloid leukemia (AML) in morphologic remission. Several conditioning regimens have been ut
Autor:
Leslie A. Andritsos, Natarajan Muthusamy, Qiuhong Zhao, John C. Byrd, Jennifer A. Woyach, Heather Breidenbach, Jeffrey Jones, Amber Gordon, Meixiao Long, Nyla A. Heerema, Caitlin Coombes, Farrukh T. Awan, Amy S. Ruppert
Publikováno v:
Blood. 128:4372-4372
Chronic Lymphocytic Leukemia (CLL) has a varied clinical course; some patients experience a long survival and others succumb to disease in a short time. Clinical factors correlated with either time to first treatment (TFT) and/or overall survival inc
Autor:
Pablo J. Muxi, Bjorn Andreasson, Peter L. Johansson, Robyn M. Scherber, Dana Ranta, Stefanie Slot, Heidi E. Kosiorek, Dolores Hernández-Maraver, Amylou C. Dueck, Xiujuan Sun, Martin Griesshammer, Ana Kerguelen Fuentes, Peihong Zhang, Francesco Passamonti, Holly L. Geyer, Federico Sackmann, Zefeng Xu, Gabriel Etienne, Deepti Radia, Frank Stegelmann, Andreas Reiter, Tiziano Barbui, Jean-Christophe Ianotto, Suzan Commandeur, Peter A. W. te Boekhorst, Zhijian Xiao, Sonja Zweegman, Harry C. Schouten, Gunnar Birgegård, Carlos Besses, Françoise Boyer, Giovanni Barosi, Ruben A. Mesa, Alessandro Rambaldi, Jean-Jacques Kiladjian, Maria Grazia Ferrari, Thomas Lehmann, Heike L. Pahl, Lydia Roy, Jan Samuelsson, Francisco Cervantes, Alessandro M. Vannucchi, Konstanze Döhner, Yue Zhang, Karin Bonatz, Junqing Xu, Robert Peter Gale, Norman Maldonado, Jean-Yves Cahn, Claire N. Harrison
Publikováno v:
Blood. 126:4080-4080
Background Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) associated with a high degree of symptomatology, progressive cytopenias and potential to transform into acute myelogenous leukemia (AML). Thrombocytopenia amongst MF patients
Autor:
Joseph Pidala, Mukta Arora, Paul J. Martin, Xiaoyu Chai, Barry E. Storer, Jeanne Palmer, Madan Jagasia, Mary E.D. Flowers, Corey Cutler, Stephanie J. Lee, Sally Arai, Yoshihiro Inamoto, Steven Z. Pavletic, Georgia B. Vogelsang, Daniel J. Weisdorf
Publikováno v:
Blood. 122:4614-4614
The global severity score (GS) was devised by experts during the 2005 NIH Consensus for chronic graft-versus-host disease (GVHD) to reflect the overall severity of chronic GVHD at any time point. According to this scale, overall involvement is catego